Rapport Therapeutics (RAPP) EBITDA (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of EBITDA data on file, last reported at -$24.2 million in Q1 2026.

• On a quarterly basis, EBITDA rose 10.67% year-over-year to -$24.2 million in Q1 2026; TTM through Mar 2026 was -$122.2 million, a 31.31% decrease from a year earlier, with the FY2025 full-year figure at -$125.1 million, down 50.62% from the prior year.
• EBITDA for Q1 2026 stood at -$24.2 million, up from -$38.5 million in the prior quarter.
• Over the last five years, EBITDA for RAPP reached as high as -$6.6 million in Q2 2023 and fell as low as -$38.5 million in Q4 2025.
• Historically, EBITDA has averaged -$21.9 million across 4 years, with a median of -$22.6 million in 2024.
• Across the five-year window, EBITDA plunged 213.73% in 2024 and rose 10.67% in 2026, its largest moves.
• Year by year, EBITDA stood at -$14.8 million in 2023, then sank by 58.99% to -$23.5 million in 2024, then sank by 63.72% to -$38.5 million in 2025, then surged by 37.12% to -$24.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$24.2 million in Q1 2026, -$38.5 million in Q4 2025, and -$30.0 million in Q3 2025.